New York, July 28, 2022 (GLOBE NEWSWIRE) — According to the Lancet Respiratory Medicine, approximately 545 million people worldwide suffered from chronic respiratory disease in 2017, a 39.8% increase since 1990. In addition, according to the World Health Organization (WHO), around 262 million people suffered from asthma in 2019 and approximately 455,000 died worldwide people on it.

Research Nester has published an in-depth market report on “Global market for long-acting beta agonists‘ for the forecast period i.e. 2022-2031, which includes the ongoing industry innovations and recent trends that are being adopted by the major players in the industry to achieve their business goals. Apart from that, the comprehensive data on market size, growth rate, market revenue share, growth opportunities, and challenges faced by the market players along with a worldwide analysis of five major regions namely North America, Latin America, Europe, Asia Pacific and the Middle East & Africa have been provided in the report.

According to the World Health Organization (WHO), approximately 3.23 million people died from COPD in 2019. Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. The global Long-Acting Beta-Agonists (LABAs) market is anticipated to grow at a CAGR of ~9% during the forecast period. Lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, and others are treated with long-acting beta-agonists (LABAs), which are inhaled drugs. The market is expected to grow due to the increasing prevalence of lung diseases worldwide. These diseases are more common in people who grew up or currently live in urban areas. In addition, the risk of respiratory diseases is higher in obese or overweight children and adults. The increase in urban population and increasing prevalence of obesity are estimated to drive the global market growth over the forecast period. According to the United Nations (UN) of 751 million…